

Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group.

Title: Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group.

Publication year: 2020

Journal: Neurologia

Authors: Unidad de Cefaleas y Neuralgias, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: noemimorollon@gmail.com.

Society: Spanish Society of Neurology's Headache Study Group

Origin country: Spain

Target countries: Spain

DOI: 10.1016/j.nrl.2020.07.007

PMID: 32896463

Source: <https://pubmed.ncbi.nlm.nih.gov/32896463/>

pmc Neurologia (Engl Ed) Neurologia (Engl Ed) 3815 pheelsevier 101778590 Neurologia (Barcelona, Spain) 2173-5808 pmc-is-collection-domain yes pmc-collection-title Elsevier - PMC COVID-19 Collection PMC7546192 PMC7546192.1 7546192 7546192 32896463 10.1016/j.nrleng.2020.07.008 S2173-5808(20)30217-0 1 Original Article Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group ■ Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología Morollón N. a ■ Belvis R. a De Dios A. b Pagès N. b González-Oria C. c Latorre G. d Santos-Lasaosa S. e a Unidad de Cefaleas y Neuralgias, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain b Servicio de Farmacia Hospitalaria, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain c Unidad de Cefaleas, Servicio de Neurología, Hospital Universitario de Fuenlabrada, Madrid, Spain d Unidad de Cefaleas, Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, Spain e Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón (IIS-Aragón), Zaragoza, Spain ■ Corresponding author. November-December 2020 9 10 2020 35 9 366599 628 632 14 6 2020 19 7 2020 09 10 2020 13 10 2020 18 04 2024 © 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. 2020 Sociedad Española de Neurología Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología 35 9 28 7 2020 628 632 Neurologia (Barcelona, Spain) 10.1016/j.nrl.2020.07.007 PMC7386293 38620330 Introduction In recent months, doubts have arisen among patients, general practitioners, and neurologists as to whether some drugs commonly used in patients with headaches and neuralgia may favour or complicate the disease caused by SARS-CoV-2.

We collected information on the opinions of scientific societies and medicines agencies (American, European, and Spanish) to clarify doubts regarding the use of drugs such as lisinopril, candesartan, ibuprofen, corticosteroids, carbamazepine, and monoclonal antibodies targeting the calcitonin gene-related peptide in the context of the COVID-19 pandemic.

We make recommendations about the use of standard headache treatments in the context of the COVID-19 pandemic, based on the current scientific evidence.

At present, there is no robust scientific argument to formally contraindicate any of the standard treatments employed for headaches and neuralgias.

En los últimos meses han surgido dudas por parte de pacientes, médicos de familia y neurólogos sobre la posibilidad de que algunos de los fármacos que habitualmente se utilizan en cefaleas y neuralgias puedan facilitar o complicar la infección por el SARS-CoV-2.

Hemos recabado información sobre el posicionamiento de sociedades científicas, así como de las distintas Agencias de Medicamentos (americana, europea y española) para poder esclarecer dudas respecto al uso de fármacos como lisinopril, candesartán, ibuprofeno, corticoides, carbamazepina, anticuerpos monoclonales contra el CGRP durante la pandemia por COVID-19.

Planteamos recomendaciones acerca del uso de fármacos habituales en el tratamiento de las cefaleas en el contexto de la pandemia por COVID-19, basándonos en las evidencias de las que disponemos en el momento actual.

Actualmente, no existe ningún argumento científico robusto para contraindicar formalmente ninguno de los tratamientos que se emplean en cefaleas y neuralgias.

In the light of numerous questions raised in recent months by patients, family doctors, and neurologists about the possibility that certain drugs habitually used to treat headache and neuralgia may promote or complicate SARS-CoV-2 infection, the Spanish Society of Neurology's Headache Study Group wishes to make the following statement:

This hypothesis is based on a limited number of studies that do not address this subject as the main objective, and use in vitro or experimental models of poor quality, which do not contribute scientific evidence. Nonetheless, their conclusions have been exaggerated by certain media outlets, causing concern among the general population and healthcare professionals.

No scientific or neurological organisation has yet taken a position on the treatment of existing headache in patients with COVID-19; so far, the literature only includes opinion articles. We also consider it important to address this issue in the light of recent evidence of new-onset headache in patients with COVID-19, and the implications for their treatment. 1 , 2 , 3 Therefore, we issue the following detailed recommendations on the drugs concerned.

These drugs are indicated for the preventive treatment of migraine, with level of evidence 2 and grade of recommendation B. 4 Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor and candesartan is an angiotensin receptor II blocker (ARB). These are the only renin-angiotensin system inhibitors used in the treatment of migraine.

ACE inhibition prevents the conversion of angiotensin I into angiotensin II, which has potent vasoconstrictive effects and regulates aldosterone release by the adrenal glands.

ACE is produced in various tissues, including in the central nervous system, kidneys, and lungs. ACE2 is an enzyme homologous to ACE, and is responsible for the degradation of angiotensin II to angiotensin; therefore, its physiological effect is opposite to that of ACE. ACE2 is a membrane enzyme that regulates the entry of the SARS-CoV-2 virus into cells. In humans, ACE inhibitors inhibit ACE but not ACE2, although animal studies have found that both ACE inhibitors and ARBs upregulate ACE2 expression when administered in high doses. 5 , 6 , 7 , 8

International, European, and American organisations 9 , 10 , 11 , 12 consider ACE inhibitors and ARBs not to be contraindicated in hypertensive patients with suspected or confirmed COVID-19: these drugs may even be beneficial, if upregulation of ACE2 leads to decreased angiotensin II levels in the lungs. Furthermore, withdrawing these drugs may exacerbate the underlying cardiovascular or kidney disease in some patients, leading to greater mortality rates. Therefore, their suspension is also not indicated in patients with migraine.

Nonetheless, we recommend not beginning preventive treatment of migraine with these drugs in the context of the COVID-19 pandemic. Other treatment options are available when first-line treatments have been exhausted; these include venlafaxine (level of evidence 2, grade of recommendation B), zonisamide (level of evidence 4), and lamotrigine (level of evidence 4). 4 We also recommend evaluating other treatment options in patients already taking lisinopril or candesartan for migraine and presenting risk factors for severe COVID-19 (Table 1). Table 1 Risk factors for severe COVID-19 proposed by the United States Centers for Disease Control and Prevention.

Ibuprofen is indicated for acute episodes of migraine of moderate intensity, with level of evidence 1 and grade of recommendation A. 4

Without a doubt, this is the drug that has been subject to the greatest controversy and raised the most concern, as it is one of the most widely used drugs worldwide for the symptomatic treatment of migraine attacks. The concerns about ibuprofen originated in an article published in The Lancet on 11 March 2020, warning that ibuprofen may increase ACE2 expression, leading to clinical worsening of COVID-19. 13 Eight days later, the World Health Organization announced this finding, but issued a correction shortly thereafter, stating that there was no scientific evidence supporting this claim. The United States Food and Drug Administration, European Medicines Agency, and Spanish Agency of Medicines and Medical Devices have issued statements to the same effect, and recommend that research be done on the subject. 14 , 15 , 16 The possible association between exacerbation of SARS-CoV-2 infection and treatment with ibuprofen and ketoprofen is being evaluated by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee. In rats, ibuprofen increases ACE2 levels in the heart only; this effect has not been observed in other organs. 8 , 17 It should be noted that the dose used in the experimental animals is equivalent to 3 g in humans, whereas the maximum recommended dose for migraine treatment is 1800 g/day. 4

Therefore, we recommend avoiding new indication of ibuprofen only in patients with migraine and presenting risk factors for severe COVID-19 (Table 1). In patients already using the drug, we do not recommend changing the treatment, although physicians should advise patients to avoid excess consumption of ibuprofen (more than 15 pills/month).

It should also be noted that alternative drugs are available for treating moderate migraine attacks; these include naproxen, indometacin, and diclofenac. Finally, triptans can also be used: these drugs are indicated for moderate-severe migraine attacks.

Corticosteroids are indicated as a transitional preventive treatment for cluster headache and for the treatment of status migrainosus (level of evidence 4 and grade of recommendation C for both indications). 4

Indication of these drugs to treat COVID-19 is controversial. The United States Centers for Disease Control and Prevention contraindicate corticosteroids based on previous experience with the 2003 SARS-CoV epidemic, when several articles reported that early use of corticosteroids was associated with higher plasma viral load and delayed viral clearance. 18 However, they may be beneficial in the early stage of SARS-CoV-2 infection, reducing the duration of mechanical ventilation and overall mortality rates in patients with established moderate-to-severe adult respiratory distress syndrome 19 ; no randomised studies have been performed, however. 20

As corticosteroids are known to cause immunosuppression, we recommend avoiding the habitual indication of 1 mg/kg orally in patients with cluster headache during the pandemic and extending the use of occipital nerve block with triamcinolone, methylprednisolone, or betamethasone; these drugs have the same level of evidence and practically no systemic effects, since the corticosteroid is injected locally. 4 Clinical guidelines also mention other treatment options for delayed preventive treatment, including verapamil (level of evidence 1, grade of recommendation A), lithium carbonate (level of evidence 2, grade of recommendation B), topiramate (level of evidence 2, grade of recommendation B), valproic acid (level of evidence 4, grade of recommendation C), gabapentin (third-line treatment), and botulinum toxin A. 4

Parenteral or oral corticosteroids are also used to treat status migrainosus in emergency departments 4 ; however, as they are prescribed for very short schedules, we do not recommend avoiding them, except in cases of strong suspicion or diagnosis of severe COVID-19 (Table 1).

Carbamazepine is indicated for the treatment of trigeminal neuralgia, with level of evidence 1 and grade of recommendation A. 4

No study has addressed the relationship between the drug and COVID-19; however, given that its potential adverse effects include leukopaenia, we recommend considering other options before indicating it as a new treatment, especially in patients with risk factors for severe COVID-19 (Table 1). COVID-19 typically presents with lymphocytopaenia, which may be exacerbated by carbamazepine-induced leukopaenia. Patients not presenting risk factors for severe COVID-19 (Table 1) and who have already been receiving the drug for over 3 months should be monitored with laboratory blood analyses. This recommendation should also be extended on an individual basis to patients with trigeminal neuralgia taking sodium channel blockers: eslicarbazepine acetate, oxcarbazepine (level of evidence 4, grade of recommendation C), and lamotrigine (level of evidence 2, grade of recommendation B). Other treatment options are available, including pregabalin, gabapentin, baclofen (level of evidence 4, grade of recommendation C), and botulinum toxin A. 4

Published trials and clinical experience have shown that treatment of migraine with anti-CGRP monoclonal antibodies does not increase the risk of infection or immunosuppression, as they seem not to compromise the immune system. Therefore, we do not recommend suspending this treatment during the pandemic.

The literature includes studies of MERS-CoV and SARS-CoV infection in patients receiving immunomodulatory or immunosuppressive treatment. Disease progression and mortality rates were not worse in patients receiving immunosuppressants, chemotherapy, or organ transplants. 21

In the current pandemic, case series have been published of patients undergoing organ transplantation 22 , 23 or receiving immunomodulatory treatment for multiple sclerosis 24 ; poorer prognosis is not reported in these patients.

Furthermore, it has been suggested that these treatments may have a protective effect: through their influence on lymphocytes, they may block the cytokine storm occurring in the most severe cases of infection. A clinical trial is also underway into the treatment of COVID-19 with fingolimod, which induces lymphocytopaenia through lymphocyte sequestration. 25 However, insufficient information is available to support or reject this hypothesis.

It is essential to take precautions against potential interactions between preventive treatments for migraine, such as amitriptyline, beta blockers, verapamil, mirtazapine, and valproic acid, and drugs used to treat COVID-19, such as lopinavir/ritonavir, hydroxychloroquine, chloroquine, and azithromycin. 26

The majority of these drug-drug interactions are classed as risk category C; therefore, the joint use of these drugs is not contraindicated, but close monitoring is needed to prevent adverse reactions or loss of efficacy.

The authors have no conflicts of interest to declare.

10.1111/head.13856 . [published online ahead of print, 2020 May 15]. PMC7272895 32412101 2 Carod-Artal F.J. Neurological complications of coronavirus and COVID-19 *Rev Neurol* 70 2020 311 322 32329044 10.33588/rn.7009.2020179 3 Belvis R. Headaches during COVID-19: my clinical case and review of the literature. *Headache*. 10.1111/head.13841 . [published online ahead of print, 2020 May 15]. PMC7273035 32413158 4 Ezpeleta D. Pozo-Rosich P. Guidelines of the Spanish Society of Neurology for the diagnoses and treatment of headaches 2015 Ed. Luzon 5 SA Madrid 5 Ferrario C.M. Jessup J. Chappell M. Averill D.B. Brosnihan K.B. Tallant E.A. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 *Circulation* 111 2005 2605 2610 15897343 10.1161/CIRCULATIONAHA.104.510461 6 Soler M.J. Ye M. Wysocki J. William J. Lloveras J. Battle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan *Am J Physiol Ren Physiol* 296 2009 F398 F405 10.1152/ajprenal.90488.2008 19004932 7 Wang X. Ye Y. Gong H. Wu J. Yuan J. Wang S. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang (1-7)-mas axes in pressure overload-induced cardiac remodeling in male mice *J Mol Cell Cardiol* 97 2016 180 190 27210827 10.1016/j.yjmcc.2016.05.012 8 MaassenVanDenBrink A. de Vries T. Danser A.H.J. Headache medication and the COVID-19 pandemic *J Headache Pain* 21 2020 38 32334535 10.1186/s10194-020-01106-5 PMC7183387 9 American Heart Association, Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Available from: <https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician> 10 European Society of Hypertension, <https://www.eshonline.org/spotlights/eshstatement-on-covid-19/> . 11 World Health Organization Could Ibuprofen Worsen Disease for People With COVID-19? 2020 World Health Organization Geneva 12 European Medicines Agency. EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic. Available from: <https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic> . 13 Fang L. Karakioulakis G. Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* 8 2020 e21 10.1016/S2213-2600(20)30116-8 32171062 PMC7118626 14 Food and Drug Administration. FDA Advises Patients on Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for COVID-19. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19> . 15 .Agencia Española de Medicamentos y Productos Sanitarios. La AEMPS informa que ningún dato indica que el ibuprofeno agrave las infecciones por COVID-19. Available from: <https://www.aemps.gob.es/informa/notas-informativas/medicamentos-uso-humano-3/2020-medicamentos-uso-humano-3/la-aemps-informa-que-ningun-dato-indica-que-el-ibuprofeno-agrave-las-infecciones-por-covid-19/> 16 European Medicines Agency EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. Available from: <https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19> 2020 17 Qiao W. Wang C. Chen B. Zhang F. Liu Y. Lu Q. Ibuprofen attenuates cardiac fibrosis in streptozotocin induced diabetic rats *Cardiology* 131 2015 97 106 25896805 10.1159/000375362 18 Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinicalguidance_management_patients . 19 Kanoh S. Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications *Clin Microbiol Rev* 23 2010 590 615 20610825 10.1128/CMR.00078-09 PMC2901655 20 Villar J. Ferrando C. Martínez D. Ambrós A. Muñoz T. Soler J.A. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial *Lancet Respir Med* 8 2020 267 276 32043986 10.1016/S2213-2600(19)30417-5 21 Assiri A. Al-Tawfiq J.A. Al-Rabeeah A.A. Al-Rabiah F.A.

Al-Hajjar S. Al-Barrak A. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study *Lancet Infect Dis* 13 2013 752 761 23891402 10.1016/S1473-3099(13)70204-4 PMC7185445 22

Montagud-Marrahi E. Cofan F. Torregrosa J.V. Cucchiari D. Ventura-Aguilar P. Revuelta I. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients *Am J Transplant* 10 2020 10.1111/ajt.15970 PMC7267297 32368838 23

Tschopp J. L'Huillier A.G. Mombelli M. Mueller N.J. Khanna N. Garzoni C. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study *Am J Transplant* 10 2020 10.1111/ajt.16062 PMC7272999 32412159 24

Sormani M.P. Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis *Lancet Neurol* 19 2020 481 482 32359409 10.1016/S1474-4422(20)30147-2 PMC7191287 25

Wang N. First Affiliated Hospital of Fujian Medical University. Fingolimod en COVID-19. *ClinicalTrials.gov*. Available from: <https://clinicaltrials.gov/ct2/show/NCT04280588> . 26

Ezpeleta D. García Azorín D. Manual Covid-19 para el neurólogo general 2020 Ediciones SEN p. 68 ■ Please cite this article as: Morollón N, Belvís R, De Dios A, Pagès N, González-Oria C, Latorre G, et al. Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología. *Neurología*. 2020;35:628–632.